Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 1997

View Archived Issues

Yakult Honsha discloses ACAT inhibitors

Antiallergic agents from Hisamitsu

Terumo prepares inhibitors of smooth muscle cell proliferation

Sankyo reveals natural alpha-glucosidase inhibitor

Bone-selective estrogen derivatives claimed by Sumitomo

Daiichi discloses new antitumor agents

Antiinflammatory protein described by New York University

Genetics Institute discovers novel protein

Tokyo University researchers characterize new steroidal saponin

Novel positive inotrope discovered by Meiji Institute of Health Science

Daiichi Pharmaceutical presents novel antisecretory agent

Sepracor completes levalbuterol/racemic albuterol comparison trial

Bergen Brunswig terminates merger with IVAX

AIT-082 enters trials in patients in Canada

FDA expands indications for inactivated polio vaccine

Topamax cleared for marketing in Canada

Second approval for Zomig

Additional U.S. patent issued for Cariel

Alphagan receives first European approval

Name change for Connective Therapeutics; patient enrollment completed in pivotal interferon trial

Zeneca granted exclusivity for new formulation of propofol

Myotrophin scheduled for review in May

Sparta's i.v. formulation of busulfan enters phase I

Protein Design Labs grants license to IDEC for humanized MAb

Hoechst Marion Roussel and ARIAD establish genomics joint venture

Dolasetron effective for nausea and vomiting associated with high-dose cisplatin

Enhanced prostate cancer test reported

Two dose regimens of latanoprost compared in glaucoma patients

Inhale granted U.S. patent for pulmonary delivery of osteoporosis drug

Geron and Pharmacia & Upjohn collaborate on telomerase inhibitors

Enzo seeks U.S. patent coverage for immune system regulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...